Management of adverse renal events related to alemtuzumab treatment in multiple sclerosis: a Belgian consensus


Alemtuzumab is a humanized monoclonal antibody indicated for the treatment of adult patients with relapsing–remitting multiple sclerosis with active disease. Multiple sclerosis (MS) patients treated with alemtuzumab are at increased risk for autoimmune adverse events (thyroid disorders, immune thrombocytopenia, and renal disease). The use of alemtuzumab has… (More)
DOI: 10.1007/s13760-017-0864-x


4 Figures and Tables